CeriBell, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Xingjuan Chao
- Full Time Employees
- 281
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 360 North Pastoria Avenue Sunnyvale CA United States of America 94085
- IPO Date
- Oct 11, 2024
- CIK
- 0001861107
- Website
- ceribell.com
- Similar Companies
- Business
- CeriBell, Inc. (Nasdaq: CBLL) develops and commercializes the Ceribell System, a point-of-care electroencephalography (EEG) platform that combines portable hardware and artificial intelligence-powered algorithms for rapid diagnosis and continuous monitoring of patients at risk of seizures in acute care settings across the United States. The system comprises disposable headbands with ten non-invasive electrodes pre-filled with conductive gel; pocket-sized, battery-operated recorders that capture and wirelessly transmit EEG signals; Clarity, an AI-powered seizure detection algorithm providing real-time alerts for electrographic status epilepticus; and the Ceribell EEG Portal, a cloud-based platform enabling remote access to EEG data, signal quality comparable to conventional EEG, and seizure burden trending for clinicians. Founded in 2014 and headquartered in Sunnyvale, California, the company targets hospitals including ICUs, emergency departments, and VA systems, serving over 615 active accounts as of September 2025 with a focus on improving patient outcomes such as shorter ICU stays and better neurological recovery. Recent developments include its initial public offering in October 2024, raising $180.3 million at $17 per share; FDA 510(k) clearance in November 2025 for the next-generation Clarity algorithm; expanded Clarity clearance for neonates, preterm and up, marking the broadest age range for seizure detection; and FedRAMP high authorization in Q2 2025, unlocking access to nearly 200 VA hospitals; alongside Q3 2025 revenue of $22.6 million, up 31% year-over-year.
Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference
CeriBell Sees ‘Early Innings' Growth as Hospital Accounts and Usage Hit Records
CeriBell, Inc. (CBLL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
CeriBell, Inc. (CBLL) Q1 2026 Earnings Call Transcript
CeriBell Q1 Earnings Call Highlights
CeriBell, Inc. (CBLL) Reports Q1 Loss, Beats Revenue Estimates
Ceribell Reports First Quarter 2026 Financial Results
Ceribell to Participate in the Bank of America Securities 2026 Health Care Conference
Ceribell to Report First Quarter 2026 Financial Results on May 11, 2026
CeriBell Highlights 2026 Growth Plan at TD Cowen: 25%-29% Guide, VA Ramp, Delirium Pilot
CeriBell Conference: CFO Highlights 36% Revenue Growth, Expands EEG Platform to Pediatrics and Delirium
Brokerages Set CeriBell, Inc. (NASDAQ:CBLL) Target Price at $24.67
Allurion Technologies (NYSE:ALUR) & CeriBell (NASDAQ:CBLL) Head-To-Head Survey
Analyzing CeriBell (NASDAQ:CBLL) & Nephros (NASDAQ:NEPH)
CeriBell, Inc. (CBLL) Q4 2025 Earnings Call Transcript
CeriBell, Inc. (CBLL) Reports Q4 Loss, Beats Revenue Estimates
Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results
Ceribell to Participate in Upcoming March Investor Conferences
Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Chuck Royce's Strategic Moves: Significant Reduction in Haemonetics Corp